Luber RP, O'Neill R, Singh S, Sharma E, et al. An observational study of switching infliximab biosimilar: no adverse impact on inflammatory bowel disease control or drug levels with first or second switch. Aliment Pharmacol Ther 2021 Jul 5. doi: 10.1111/apt.16497.
PMID: 34223654